- 1 Full title: Acceptability and feasibility of tests for infection, serological testing and photography
- 2 to define need for interventions against trachoma
- 3 Short title: Acceptability and feasibility of complementary indicators for trachoma
- 4 Journal: PLoS NTD
- 5 Authors and affiliations:
- 6 Kristen K Renneker^{1,2*}, Tara B Mtuy^{1,3}, George Kabona⁴, Stephen Gabriel Mbwambo⁴, Patrick
- 7 Mosha², Jeremiah Mepukori Mollel², PJ Hooper², Paul M Emerson², T. Deirdre Hollingsworth⁵,
- 8 Robert Butcher¹, Anthony W Solomon⁶, Emma M Harding-Esch¹
- 9 1. Clinical Research Department, Faculty of Infectious and Tropical Diseases, London
- School of Hygiene & Tropical Medicine, London, United Kingdom
- 2. International Trachoma Initiative, The Task Force for Global Health, Decatur, Georgia,
- 12 United States of America
- 3. Kilimanjaro Christian Medical Centre, Moshi, Tanzania
- 4. National Neglected Tropical Diseases Control Programme, Preventive Services
- Department, Ministry of Health, Tanzania
- 5. Big Data Institute, Li Ka Shing Centre for Health Information and Discovery, University
- of Oxford, Oxford, UK
- 18 6. Global Neglected Tropical Diseases Programme, World Health Organization, Geneva,
- 19 Switzerland

*Corresponding author: Email: krenneker@taskforce.org (KKR)

Abstract (PLoS NTD word limit = 300, current word count = 300)

22

48

- Background: Trachoma causes blindness due to repeated conjunctival infection by *Chlamydia*
- 24 trachomatis (Ct). Transmission intensity is estimated, for programmatic decision-making, by
- prevalence of the clinical sign trachomatous inflammation—follicular (TF) in children aged 1–9
- years. Research into complementary indicators to field-graded TF includes work on conjunctival
- photography, tests for ocular Ct infection, and serology. The perceived acceptability and
- feasibility of these indicators among a variety of stakeholders is unknown.
- 29 Methodology: Focus group discussions (FGDs) with community members and in-depth
- 30 interviews (IDIs) with public health practitioners in Tanzania were conducted. FGDs explored
- 31 themes including participants' experience with, and thoughts about, different diagnostic
- 32 approaches. The framework method for content analysis was used. IDIs yielded lists of perceived
- strengths of, and barriers to, implementation for programmatic use of each indicator. These were
- 34 used to form an online quantitative survey on complementary indicators distributed to global
- stakeholders via meetings, mailing lists, and social media posts.
- 36 **Results:** Sixteen FGDs and 11 IDIs were conducted in October–November 2022. In general, all
- 37 proposed sample methods were deemed acceptable by community members. Common themes
- 38 included not wanting undue discomfort and a preference for tests perceived as accurate. Health
- workers noted the importance of community education for some sample types. The online survey
- was conducted in April–May 2023 with 98 starting the questionnaire and 81 completing it.
- 41 Regarding barriers to implementing diagnostics, the highest agreement items related to
- 42 feasibility, rather than acceptability. No evidence of significant differences was found in
- responses pertaining to community acceptability based on participant characteristics.
- 44 Conclusions: All of the indicators included were generally deemed acceptable by all
- 45 stakeholders in Tanzania, although community education around the benefits and risks of
- different sample types, as well as addressing issues around feasibility, will be key to successful,
- 47 sustainable integration of these indicators into trachoma programs.

Author Summary (limit = 200, current = 200) 50 Trachoma is a disease that causes blindness through conjunctival infection with the bacterium 51 Chlamydia trachomatis. Trachoma is targeted for global elimination by 2030. To know whether 52 53 population-level interventions are required, we must know how intensely conjunctival C. trachomatis is being transmitted in a population. The current proxy recommended by the World 54 55 Health Organization is prevalence of a clinical sign of active (inflammatory) trachoma: 56 trachomatous inflammation—follicular. However, this indicator has several drawbacks. Policy-57 makers are considering the utility of a number of complementary indicators, including conjunctival photography and tests for infection and serology. 58 We sought the opinions of different stakeholders to determine the acceptability and feasibility of 59 complementary indicators for use in trachoma programs. In Tanzania, we undertook focus group 60 61 discussions with community members and in-depth interviews with public health practitioners. We also conducted an online survey of global stakeholders. We found that all the proposed test 62 types were acceptable to stakeholders in Tanzania; common themes included not wanting undue 63 discomfort and a preference for test types perceived to be accurate. Community education and 64 building trust was deemed critical. From the online survey, the most agreed-upon barriers to 65 66 implementation of each method were related to concerns about feasibility, rather than acceptability. 67

Introduction

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

Trachoma is a neglected tropical disease (NTD) that causes blindness as a result of repeated conjunctival infection by the bacterium *Chlamydia trachomatis* (Ct). Transmission intensity is estimated, for programmatic decision-making, via field grading of the clinical sign trachomatous inflammation—follicular (TF). A major goal of the World Health Organization (WHO) Alliance for the Global Elimination of Trachoma is the reduction of TF prevalence in 1– 9-year-olds (TF_{1-9}) to <5% in all formerly endemic districts worldwide, contributing to the achievement of global elimination of trachoma as a public health problem.² A key component of the WHO-recommended SAFE (surgery, antibiotics, promotion of facial cleanliness and environmental improvement) strategy that is designed to be used to achieve this target is mass drug administration (MDA) of antibiotics to clear infection. The number of MDA rounds is dependent on the category of TF_{1-9} within an evaluation unit (generally equivalent to a district) as measured by population-based prevalence surveys³ on the assumption that TF_{1-9} is wellcorrelated with prevalence of Ct infection. However, TF₁₋₉ has several limitations as the sole indicator for trachoma. First, the relationship between TF₁₋₉ and infection is not predictable, ⁴ especially post-MDA, ⁵ and the reduction in TF_{1-9} often lags behind the reduction in Ct infection. Second, conjunctival follicles (the features that lead to a diagnosis of TF) are not necessarily specific to trachoma, sometimes occurring due to other causes. Furthermore, in areas with low prevalence of trachoma, it becomes both costlier to train field graders⁸ and more difficult for graders to pass the inter-grader agreement test.9-11 There has been ongoing research into indicators that could be alternative or complementary to TF, including conjunctival photography, ¹² tests for ocular Ct infection, ⁵ and serology to assess an individuals' previous exposure to Ct infection by detecting antibodies to the pathogen.¹³ It is important to note that each of these indicators measures a different signal: clinical grading (both field-based and through photography) measures signs of inflammation, infection tests are a direct measure of current infection with *Ct*, and serology measures a history of previous exposure to the pathogen. Therefore, each of these indicators could provide different measures of the public-health threat caused by trachoma; i.e., indicators should be considered "complementary" rather than "alternative" to each other.

Following a WHO meeting in 2016 reviewing existing data, it was concluded that there was insufficient evidence to support routine use of Ct infection or serology tests to inform trachoma elimination programs. However, a WHO informal workshop in December 2021 supported the use of age-stratified data on Ct infection and serological data on the presence of anti-Ct antibodies for decision-making in districts where TF_{1-9} either remains at or above the 5% elimination threshold at the second impact survey (districts with "persistent" TF) following MDA interventions, or falls <5% but subsequently returns to \geq 5% during the surveillance period after cessation of MDA (districts with "recrudescent" TF). The second impact TF is a surveillance TF in TF i

WHO is now producing guidelines on the use of serology in trachoma elimination programs. As part of the guideline development process, the Guideline Development Group must consider both the acceptability of the proposed intervention and the values and preferences of the people affected by the recommendations, which will partially determine the strength of any recommendations. Research to date has indicated the value complementary indicators could have for trachoma surveillance purposes. A literature review assessing post-elimination surveillance systems for multiple diseases, including trachoma, suggested that opportunities for inclusion of infection testing and serological markers in trachoma elimination settings continue to be explored. A 2019 survey of stakeholders found that the top-cited barrier to trachoma

116

117

118

119

120

121

122

123

124

125126

127

128

129

130

131

132

133

134

135

136


137

138

eradication is inadequate surveillance tools and systems to monitor for recrudescence. 18 While eradication is a different goal than elimination as a public health problem, the need for practical strategies to measure trachoma after the cessation of MDA remains. With 2030 as the target for global elimination of trachoma as a public health problem, ¹⁹ a better understanding of the acceptability and feasibility of complementary indicators for trachoma detection by all stakeholders is urgently needed. In this study, we aimed to determine the opinion of a wide variety of stakeholders through a mixed-methods approach: a qualitative study of community members and public health practitioners in Tanzania, followed by a quantitative online global survey of stakeholders. Methods **Qualitative study in Tanzania Ethics** The qualitative study was approved by the London School of Hygiene & Tropical Medicine Research Ethics Committee (Ref: 28028), the Task Force for Global Health ethical review body, and Tanzania's National Institute of Medical Research (Ref: NIMR/HQ/R.8a/Vol.IX/4123). Work was conducted in collaboration with Tanzania's health ministry through the National NTD Control Programme, region- and district-level health departments, and village leaders. Written, informed consent was obtained from all participants prior to their inclusion by trained research assistants fluent in the local languages (Swahili and/or Maa) with an impartial witness present for illiterate participants. Permission to record the focus group discussions (FGDs) and in-depth interviews (IDIs) and publish quotes was obtained at enrollment. Setting/Sampling Tanzania was chosen based on the support of its health ministry, history and strength of its trachoma program, presence of districts with persistent and recrudescent TF as well as districts

having met the elimination threshold, and access to the "Maasai corridor", an area spanning the Kenya-Tanzania border with high levels of persistent and recrudescent TF among pastoralists including the Maasai ethnic group. FGDs with community members were conducted in four districts in Tanzania, consisting of two districts with $TF_{1-9} < 5\%$ and two with $TF_{1-9} \ge 5\%$ at most recent survey, chosen to be representative of pre- and post-elimination settings. Districts were chosen in three selected regions (Dodoma, Singida, and Arusha) to ensure a diversity of trachoma program experience, geographic location, and ethnic group. The current TF_{1-9} category in Tanzania and the four selected districts are shown in Figure 1. Within each chosen district, two villages were randomly selected for the FGDs by assembling a list of all villages in each district, assigning each village a random number, and selecting the two villages with the lowest randomly generated numbers.

Figure 1: Map of the four districts selected for the study and their current trachomatous inflammation—follicular (TF) prevalence category in children 1–9-years-old, Tanzania. The boundaries and names shown and the designations used on this map do not imply the expression of any opinion whatsoever on the part of the authors, or the institutions with which they are affiliated, concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Prevalence map source: Trachoma Atlas.²⁰



For the FGDs, community members aged 18–60 years who had experience caring for children were eligible to participate. Participants were identified using a snowball sampling approach, ²¹ with index participants chosen by the village leader. Snowball sampling continued until the target group size (n=10) for each FGD was reached. Separate FGDs were held with men and women.

IDIs were conducted with public health practitioners in Tanzania. We sought interviews with a wide variety of public health practitioners, including laboratory personnel, NTD program officers, and non-governmental organization (NGO) program staff at all levels. Participants were

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

selected based on experience working in NTD programs and their availability, with a target of 2-3 respondents for each of the three regions selected for FGDs, plus practitioners at the national level who were based in Dodoma. Data collection FGDs and IDIs were conducted by trained research assistants in the participants' preferred language using pre-designed topic guides (Supplemental File 1), exploring themes such as previous experience with each of the test types: TF status via field grading and photography, infection testing, and serology, as well as (for community members) thoughts about the different sample collection methods: field grading, conjunctival photography, eye swabs, and dried blood spots, and (for public health practitioners) thoughts about the feasibility of each test type. In the FGDs, visual aids were used to help participants understand the different sample collection methods. Sessions were recorded using an electronic audio recorder, transcribed by a native speaker and then translated by them into English. Translations were checked for accuracy by the researcher who carried out data collection. Data analysis Transcripts were entered into the qualitative data management software Nvivo²² and coded based on both an a priori list of codes pertaining to each test type (Supplemental File 2) as well as broader emergent themes. The framework method for content analysis ²³ was used to chart data into a framework matrix. For the FGDs, comparative analysis was done to compare responses between communities based on gender and setting ($TF_{1-9} \ge 5\%$ or $TF_{1-9} < 5\%$). The coding framework and analysis plan were reviewed by a second researcher prior to finalization of analysis. For the IDIs, responses pertaining to strengths and barriers for each of the sample types were used to formulate the stakeholder survey questionnaire.

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

Quantitative survey of stakeholders **Ethics** The quantitative survey was approved by the London School of Hygiene & Tropical Medicine Research Ethics Committee (Ref: 28589) and the Task Force for Global Health ethical review body. Informed consent was obtained electronically in the preferred language of the participant, from the four languages available: English, Spanish, French, and Portuguese. All questions (other than consent) were optional, and the survey responses were anonymous. At the end of the survey window, survey data were downloaded from SurveyMonkey²⁴ prior to deletion of the survey and data from the platform. Setting/sampling Stakeholders working in trachoma, including national program coordinators or other national program staff, members of NGOs, donor organizations, and academic organizations were asked to participate in an online survey to assess their agreement with the strengths and barriers to each test type identified by the IDIs with Tanzanian public health practitioners. Stakeholders were required to be over the age of 18 years. A list of email addresses of stakeholders meeting these inclusion criteria was assembled using publicly available sources, such as organizational websites, publications, and meeting reports with participant lists. Snowball sampling was employed by asking key members of partner organizations to recommend additional stakeholders. We solicited responses from as many people as possible who met our criteria. Data collection The online survey began during the annual meeting of the WHO Alliance for the Global Elimination of Trachoma by 2020 (GET2020) held in Istanbul, Turkïye, in April 2023. The GET2020 meeting convenes a variety of stakeholders; representatives from all trachomaendemic, formerly-endemic, and suspected-endemic countries are invited, as well as members of related NGOs and academic or research organizations. The survey was hosted on

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

SurveyMonkey.²⁴ A link to the survey was available via email sent to the previously assembled list of email addresses, through advertisements at the GET2020 meeting, and through a post on the social media platform X (formerly known as Twitter) from EMHE. Prior to the start of the survey window, the survey was piloted with colleagues with expertise in trachoma and online survey forms to gain feedback on the questionnaire and the ease of using the survey platform. The questionnaire (Supplemental File 3) included questions on the participant's age group, gender identity, organizational role, primary country/countries of trachoma work, level of agreement with the importance of various perceived barriers to implementation at the program level and strengths for different complementary indicators on a 5-point Likert scale (with the options of: Strongly Agree, Agree, Neither Agree nor Disagree, Disagree, Strongly Disagree), and identification of further knowledge gaps remaining, entered as free text, that may prevent implementation of these indicators for trachoma surveillance. The strengths and barriers presented in the questionnaire were obtained from the responses of IDI participants. Data analysis Descriptive analysis was performed using R.²⁵ Since the total target population is unknown (due to the survey being publicly available via an online link) no response rate could be calculated. Frequency tables were created to determine the percent of respondents that strongly agreed or agreed with, neither agreed nor disagreed with, and disagreed or strongly disagreed with each proposed strength and barrier. The "strongly agree" and "agree" responses were combined and the "strongly disagree" and "disagree" responses were combined to determine the percent of respondents who agreed or disagreed with a statement, respectively. In order to determine if responses pertaining to community acceptability differed between national program staff and other stakeholders, responses pertaining to these barriers were analyzed on the basis of the participant's organizational and personal role (country staff, as defined as a respondent whose

240

241

242

243

244245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

organizational role was "Government" and personal role was "Programmatic/Implementation", compared to all other stakeholders) by calculating the median and interquartile range (IQR) of responses to these questions. The 2-tailed Wilcoxon rank-sum test was used to calculate p-values comparing the responses of the two groups. Key knowledge gaps entered by respondents as free text responses were cleaned and aggregated. Results **Qualitative study in Tanzania** Data collection took place in Tanzania from October to November 2022. A total of 160 community members participated in 16 FGDs, with ten people per FGD. The reported population of selected villages ranged from roughly 1,100 to 5,400. Equal numbers of men and women participated. Fourteen FGDs were conducted in Swahili and two were conducted in Maa. A total of 11 public health practitioners participated in IDIs. The roles of participants included current and former country-level staff, NGO staff, lab technicians, regional NTD coordinators, and one healthcare worker. The framework matrix used to assess community responses for each test type by gender and setting is provided as Supplemental File 4. TF field grading According to community members in Tanzania, key advantages of field grading of TF were the familiarity of this method (particularly noted in FGDs with women), the lack of pain or adverse consequences from this method, and the ability to receive results immediately. A perceived disadvantage of field grading of TF, mentioned in half of the FGDs, was the possibility of shortterm discomfort or adverse consequences that may be caused by the strong light of torches used as part of the field grading process:

262

263

264

265

266

267

268

269

270

271

272

273

274

275

276

277

278

279

280

281

"I think that [the] examination method of being graded with torches causes effects. For example, eyes turn red and keeps on shedding a lot of tears after a certain period of time. I recommend that they should innovate a new method for trachoma examination." (31–35-year-old woman, TF_{1-9} <5% district) In the IDIs, most of the public health practitioners who provided advantages of field grading of TF mentioned that this method is both familiar and acceptable to communities, which agrees with community feedback from the FGDs. Very few IDIs mentioned any disadvantages with field grading of TF, and most disadvantages related to general concerns with needing to train staff to conduct the examination, which is not necessarily specific to this method. None of the IDIs mentioned the possibility that communities may dislike this method due to fear of adverse consequences from the torch used as part of the examination. Conjunctival photography A majority of FGDs mentioned that a key advantage of conjunctival photography is a perceived increase in the accuracy of grading via photo versus field grading due to the ability for graders to have ample time: "It is possible that [TF field grading] won't be conducted as it is required because you are in [a] hurry but when you are taking a photo it is a good thing because a person who will examine that photo will have plenty of time to do that." (26–30-year-old man, $TF_{1-9} < 5\%$ district) Other advantages of conjunctival photography mentioned by FGD participants were the familiarity with the concept of imaging for diagnostics, and the lack of pain and adverse consequences from this method. Each of these advantages was particularly often noted in the

283

284

285

286

287

288

289

290

291

292

293

294

295

296

297

298

299

300

301

302

FGDs with men. A majority of FGDs (particularly with men) mentioned that a key disadvantage is a fear of long-term adverse consequences caused by the photo flash: "Some people are worried that when you are photographed you will go blind or your eye will be destroyed." (46–50-year-old man, TF₁₋₉ <5% district) Several FGDs (particularly those with men) also indicated a belief that conjunctival photography is not as accurate as other methods: "A photo is not enough; we would like to get another examination method because the camera won't show the disease that I have in my eyes or in my eyelid clearly." (31–35-year-old woman, $TF_{1-9} < 5\%$ district) None of the FGD participants mentioned that they had concerns related to confidentiality, usage of the photos, or the potential identifiability of photos taken. In the IDIs, none of the respondents mentioned a high level of community acceptability of conjunctival photography as a specific strength of this method. Several IDI participants mentioned that community fears related to flash photography causing adverse consequences and mistrust that the entire face would be photographed (leading to concerns by community members around the confidentiality of their and their children's images) may be potential barriers to this method. Several mentioned that education would be needed in order for communities to participate: "The most important thing is to give education and sensitization. If you will just tell a parent that you want to take a photo, he/she might think you have [a] hidden agenda with the child." (Program coordinator)

304

305

306

307

308

309

310

311

312

313

314

315

316

317

318

319

320

321

322

323

In terms of feasibility, while there was an acknowledgement from a few IDI participants that the fragility of camera equipment may be a concern in the field, most indicated that this would not be a true barrier to implementation, especially given the benefits of conjunctival photography. Eye swabs A majority of FGDs mentioned increased perceived test accuracy (especially compared to field or photo grading) as a key advantage of tests for ocular Ct infection. Half of FGDs (particularly those with men) indicated that an advantage of the test for ocular Ct infection is that this method is perceived as modern, high-tech, "professional", and/or legitimate (as it is approved by an authorizing body prior to use). Most FGDs (particularly those with men) mentioned that a key disadvantage of eye swabs is a fear of long-term adverse consequences from the test procedure: "I won't agree with the use of eye swab method, I will even tell my family members not to participate in that method because it has effects, it may leave you with a wound in the eye." (31– 35-year-old-man, $TF_{1-9} \ge 5\%$ district) In addition, half of FGDs (particularly those with men) mentioned a fear of pain from the test procedure, especially with regard to children. Several FGDs indicated that the complicated nature of the test (with the need for sample collection, storage, and testing) may cause test errors or failures. From the IDIs, many respondents said that eye swabs would be acceptable to communities only with proper education as to the risks and benefits of participation. Some IDI respondents said that training would be needed in order for the sample collector to not harm the eyes of

325

326

327

328

329

330

331

332

333

334

335

336

337

338

339

340

341

342

343

344

345

participants, with the importance of this being two-fold: to minimize harm to participants and increase participation rates: "...if the trained personnel will not be careful when taking [the] sample, she/he can harm a child and these children can inform each other that it hurts when they are taking [the] sample and this will make all children not participate in [the] examination." (Lab technician) In terms of feasibility, several IDI respondents said that a desire for samples to be processed at the local level (in order to increase turn-around time) is likely unfeasible due to a lack of current lab capacity at the district level. This was mentioned by both public health practitioners at the national and lower levels of administration. **Blood spots** Key advantages to blood spots mentioned in a majority of FGDs were the familiarity with blood testing and (particularly among FGDs with women) the lack of pain or adverse consequences from the testing procedure. Half of FGDs (particularly those with men) indicated that the high perceived accuracy of the results is an advantage to this method: "There are many diseases that cannot be seen easily but when you take a blood sample to the lab it will be a perfect solution." (51–55-year-old man, $TF_{1-9} < 5\%$ district) Several FGDs mentioned that a disadvantage to blood spots is a lack of trust by participants that the sample will be used only to test trachoma; with fears especially around testing for HIV or other sexually transmitted infections without participants' consent. Many FGDs with participants who mentioned this fear indicated that it could be mitigated with community education, as community members had simply not been made aware that the presence of antibodies to trachoma could be tested for via blood spots prior to participating in the FGDs.

347

348

349

350

351

352

353

354

355

356

357

358

359

360

361

362

363

364

365

366

One FGD among the Maasai ethnic group mentioned a general dislike of blood testing in particular: "We, as Maasai people don't like blood testing most of the time. For example, HIV and TB are prevalent in Maasai society and when people are asked to test using blood samples, they run away." (46–50-year-old woman, $TF_{1-9} \ge 5\%$ district) When IDI participants mentioned advantages of blood spots, community acceptability was not often specifically mentioned as a key strength of this method. When community acceptability was mentioned, the need for education was underscored. One IDI participant mentioned the potential for distrust related to sample use (specifically related to fears around HIV testing) among community members. Some IDI participants also mentioned the potential for community acceptability issues if community participants expect on-the-spot results (as they would receive for other types of blood tests they undergo as part of routine health care, such as malaria testing), and again underscored the need for community education as to the purpose of the test in the context of trachoma programming. In terms of feasibility, key strengths mentioned by IDI participants included the familiarity of blood spot collection and testing by health systems and the ability for high throughput of these sample types, although several participants mentioned a lack of lab capacity to store and test samples at a local level as a potential issue. While familiarity of blood testing by health systems was often mentioned, IDI respondents did not mention the potential for integration of trachoma monitoring into existing health systems via the use of blood spots as a specific advantage of this method.

368

369

370

371

372

373

374

375

376

377

378

379

380

381

382

383

384

385

386

387

388

389

When asked, the majority of FGDs had at least one participant who would hypothetically participate in each sample collection method. No qualitative difference in responses between districts with a $TF_{1-9} \ge 5\%$ vs. <5% was detected (15 FGDs in districts with a $TF_{1-9} \ge 5\%$ vs. 15 FGDs in districts with a $TF_{1-9} < 5\%$ with at least one respondent who said they would hypothetically participate in each method). FGDs with men generally indicated more willingness to hypothetically participate in all of the testing methods compared to FGDs with women (16 FGDs with men vs. 14 FGDs with women with at least one respondent who said they would hypothetically participate in each method). While responses from FGDs with men and women were largely quite similar, FGDs with men often mentioned the importance of perceived accuracy, a lack of adverse consequences from the testing procedure, and the benefit of tests perceived as modern or high tech as important to determining the acceptability of the different methods. FGDs with women mentioned the importance of test familiarity and a lack of undue discomfort or harm from participating in the test procedure as important to determining the acceptability of the different methods. **Quantitative survey of stakeholders** The online survey was live from April 24 to May 31, 2023. Responses from 98 people who consented to participate were received. Respondents reported living and working in 42 different countries and represented each trachoma-endemic WHO Region (African Region, Eastern Mediterranean Region, Region of the Americas, South-East Asia Region, and the Western Pacific Region). A majority (60%) of respondents were men. Most respondents were between the ages of 35–49 years, worked for an NGO, and worked in a programmatic/implementation role (Table 1).

Table 1: Self-reported demographic information of respondents to stakeholder survey

Characteristic	n	%
Gender		
Man	55	60%
Woman	37	40%
Age group		
18–34 years	5	5%
35–49 years	45	48%
50–64 years	32	34%
65 +	11	12%
Organizational Role		
Government	20	22%
Non-governmental organization	46	50%
University or research	22	24%
Other	4	4%
Personal Role		
Academic/Research	24	26%
Programmatic/Implementation	57	61%
Other	12	13%

Eighty-one respondents answered questions beyond providing demographic information. Table 2 includes results for questions related to respondents' agreement with strengths and barriers to each indicator. Almost all (79, 98%) of respondents agreed that TF grading being WHO-recommended for diagnosing trachoma is a strength of field grading of TF. Besides this, the strengths of field grading of TF respondents most agreed with were that TF grading is familiar (71, 88%), acceptable to communities (69, 85%), harmless/does not cause side effects (66, 81%), and that participants are provided results on-the-spot (66, 81%). The most agreed-upon barrier indicated for field grading of TF was that it is a subjective measure that is prone to human error (65, 80%).

Table 2: Stakeholder Survey – Frequency of responses to strength/barrier survey items taken from in-depth interview responses from public health practitioners in Tanzania

Survey item	3-w:
Julvevileiii	3-W

		Total respon- dents	Strongly agree or agree n (%)
Field	d grading of TF		
	TF grading is recommended by the World Health Organization for diagnosing		
	trachoma in communities.	81	79 (98
sth	TF grading is a familiar method.	81	71 (88
Strength	TF grading is acceptable to communities.	81	69 (85
Str	TF grading is harmless/does not cause side effects.	81	66 (81
	TF grading provides results on the spot.	81	66 (81
	TF grading is accurate.	79	42 (53
Barrier	TF grading is subjective and prone to human error.	81	65 (80
Bar	TF grading is not as sensitive or specific as other methods.	81	50 (62
	Everting the eyes of children can be difficult.	80	49 (61
Con	junctival photography		
	Multiple graders can grade the same photo, which will increase accuracy and help		
	determine the status of "edge cases."	73	61 (84
	Increased costs of conjunctival photography will be less than those for eye swabs or		
	blood spots.	73	41 (56
gth	The potential to use Artificial Intelligence to grade photos will provide more accurate		
Strength	results than field grading of TF.	71	34 (48
St	The photo can be used to determine the presence or absence of other eye diseases.	73	30 (41
	Conjunctival photography is easy to implement.	72	29 (40
	Grading the photo away from the field will reduce field time compared to TF grading.	73	24 (33
	Conjunctival photography is more accurate than field grading of TF.	73	21 (29)
	Conjunctival photography is more sensitive than field grading of TF.	72	18 (25
	Increased costs compared to TF grading due to need for camera equipment.	72	43 (60
	Increased costs compared to TF grading due to increased personnel training/time	70	44 /57
	needed.	72	41 (57
Barrier	Community participation may be low if participants do not receive individual results.	71	39 (55)
Ba	Community participation may be low due to fear/mistrust of having photo taken.	72	38 (53
	Conjunctival photography grading is subjective and prone to human error.	72	36 (50)
	Community participation may be low due to fear of side effects due to photo flash.	72	27 (38
Info	Conjunctival photography is perceived as less accurate compared to other methods.	73	18 (25
inie	ction testing	60	FF /01
	Infection testing can detect pre-symptomatic trachoma.	68	55 (81
Strength	Eye swabs can be tested for multiple pathogens/diseases. Infection testing is more accurate than field grading of TF at identifying trachoma.	70 70	55 (79)
	Infection testing is more accurate than ried grading of 1F at identifying trachoma.	70	54 (77
		/0	52 (74)
S	Eye swabs/infection testing are acceptable to communities as long as education is provided.	69	51 (74)
	Eye swabs have a low chance of causing side effects.	70	51 (74)
L	Lye swaps have a low chance of causing side effects.	/0	21 (12

	Extra work needed to plan for logistics of field collection and sample processing.	71	68 (96
	Desire for samples to be tested by nearest lab may be a challenge.	71	63 (89
	Increased costs compared to TF field grading due to storage of samples.	71	62 (87
	Increased costs compared to TF field grading due to equipment needed.	71	62 (87
	Requirement for cold chain a challenge due to need for stable electricity.	70	61 (87
Barrier	Increased costs compared to TF field grading due to increased personnel training/time needed.	70	48 (69
B	Poorly trained personnel might cause damage to eyes of participants.	71	40 (56
	Community participation may be low if participants do not receive individual results.	70	36 (51
	Community participation may be low due to fear of sample collection process or side effects.	70	34 (49)
	Infection testing may be less accurate than TF field grading due to time between collection and testing.	71	18 (25
Serc	ology		
	Blood spots (for other diseases) are familiar to health systems.	66	51 (77
	Blood spots are easy to collect.	66	47 (71
gth	Blood spots are easier to transport and store than eye swabs.	64	42 (66
Strength	Blood spots (for other diseases) are familiar and acceptable to community members.	66	39 (59
St	Serological testing is more accurate than TF grading at identifying trachoma.	66	29 (44
	Serological testing is fast.	65	26 (40
	Serological testing can detect pre-symptomatic trachoma.	66	21 (32
	Extra work needed to plan for logistics of field collection and sample processing.	66	58 (88
	Increased costs compared to TF field grading due to equipment needed.	66	55 (83
	Lack of current lab capacity.	65	52 (80
	Increased costs compared to TF field grading due to increased personnel training/time needed.	66	45 (68
<u>.</u>	Increased costs due to storage of samples.	65	41 (63
Barrier	Increased danger of working with blood/risk of medical errors, compared to other diagnostics.	66	38 (58)
	Field conditions challenging, samples may be destroyed in the field.	66	35 (53
	Community participation may be low due to misunderstanding or mistrust of test purpose.	66	35 (53)
	Community participation may be low if participants do not receive individual results.	64	31 (48
	Community participation may be low due to fear of finger pricking.	66	28 (42

TF = trachomatous inflammation—follicular

The most agreed-upon strength for conjunctival photography was that multiple graders can grade the same photo, increasing accuracy and helping to determine the status of borderline cases (61, 84%). In contrast, a third of respondents (24, 33%) said that a strength of conjunctival photography is that the ability to grade the photo away from the field would reduce field time.

408

409

410

411

412

413

414

415

416

417

418

419

420

421

422

423

424

425

426

427

428

429

The most agreed-upon barrier to implementation of conjunctival photography is that it would increase the costs compared to TF field grading due to the need for camera equipment (43, 60%), followed closely by increased costs due to the need for increased personnel training and time (41, 57%). For infection testing, the most agreed-upon strength was this indicator's ability to detect infection in the absence of clinical signs (55, 81%). The most agreed-upon barriers for this indicator all pertain to challenges around the feasibility of implementation, including the extra work required to plan for logistics of field collection and sample processing (68, 96%), the challenge posed by a desire for samples to be tested by the nearest lab (63, 89%), increased costs compared to field grading of TF posed by the need to store samples (62, 87%) and purchase needed equipment (62, 87%), as well as the challenge posed by the requirement for maintaining a cold chain (61, 87%). In contrast to items about feasibility, there were lower levels of agreement with barriers related to low community participation, due either to a lack of receiving individual results (36, 51%), or fear of the sample collection process or side effects (34, 49%). The most agreed-with strengths of serology include the familiarity of health systems with blood spots (for other diseases) (51, 77%), as well as an acknowledgement that blood spots are both easy to collect (47, 71%), and easier to transport and store compared to eye swabs (42, 66%). The most agreed-with barriers to the implementation of serology included the extra work needed to plan for the logistics of field collection and sample processing (58, 88%), the increased costs compared to TF field grading due to equipment needed (55, 83%), and the lack of current lab capacity (52, 80%). Less than half of respondents agreed that community participation may be low if participants do not receive individual test results (31, 48%) or due to a fear of finger pricking (28, 42%).

The results of the comparison of responses to barriers related to community acceptability by country staff vs. other stakeholders are presented in Table 3. (In this analysis, a higher score indicates a stronger level of agreement that the statement is a barrier to implementation of the indicator.) Country staff had a higher agreement compared to other stakeholders that barriers around community acceptability of conjunctival photography would pose a challenge to implementation of this indicator, while other stakeholders had higher agreement that barriers related to community acceptability of serology would pose a challenge to implementation of this indicator. However, none of the comparisons were significant at an alpha of 0.05.

Table 3: Stakeholder agreement with proposed barriers of complementary indicators to trachomatous inflammation—follicular detection by affiliation (country staff vs. other stakeholders)

	Country staff ^a (n=14)	Other stakeholders (n=59) ^b	
Barrier	median (IQR)	median (IQR)	p value ^c
Conjunctival photography			
Community participation may be low due to fear/mistrust of having photo taken.	4.0 (3.6–4.4)	3.0 (2.0–4.0)	0.13
Community participation may be low due to fear of side effects due to photo flash.	3.5 (2.5–4.5)	3.0 (2.0–4.0)	0.46
Community participation may be low if participants do not receive individual results.	4.0 (3.5–4.5)	4.0 (3.5–4.5)	0.37
Infection testing			
Community participation may be low due to fear of sample collection process or side effects.	3.0 (2.0–4.0)	3.5 (2.5–4.5)	0.70
Community participation may be low if participants do not receive individual results.	4.0 (3.4–4.6)	3.5 (3.0–4.0)	0.67
Serology			
Community participation may be low due to fear of finger pricking.	2.0 (1.1–2.9)	3.0 (2.0–4.0)	0.08
Community participation may be low due to misunderstanding or mistrust of test purpose.	3.0 (2.1–3.9)	4.0 (3.5–4.5)	0.38

Community participation may be low if participants do not			
receive individual results.	2.5 (1.6–3.4)	4.0 (3.0–5.0)	0.14

IQR = Interquartile range, a: organizational role = "Government" and personal role =

Note: A higher score indicates a stronger level of agreement that the statement is a barrier to implementation of the indicator.

Key knowledge gaps entered by respondents are presented as Supplemental File 5. Categories of knowledge gaps identified include: setting and interpreting meaningful thresholds using complementary indicators, understanding test characteristics (e.g. sensitivity and specificity) of each indicator, refining survey design to allow the inclusion of complementary indicators, interpreting serological data, understanding clinical signs and the progression of disease, integrating complementary indicators for trachoma into existing systems, understanding the acceptability and feasibility of complementary indicators, and identifying and mitigating potential issues with training and lab quality assurance.

Discussion

From the FGDs, we found that each diagnostic method explored was generally acceptable to community members in Tanzania, with key themes such as not wanting to suffer harm from the diagnostic process and the importance of (perceived) test accuracy apparent. From the IDIs with public health practitioners in Tanzania, we found that these health workers also considered each diagnostic method to be acceptable to community members, as long as appropriate education on the risks and benefits of participation is provided.

When global stakeholders were asked to indicate their agreement that given barriers would hinder implementation of complementary indicators, the highest agreement items tended to be those around feasibility, rather than acceptability. The highest consensus of any strength or barrier listed was agreement that the WHO recommendation for field grading of TF is a benefit

[&]quot;Programmatic/Implementation", b: not all respondents answered every question, c: as measured by a 2-tailed Wilcoxon-rank-sum test.

of this method, with 98% of respondents in agreement. When results around community acceptability were stratified based on country staff vs. other stakeholder, no statistically significant differences were found, indicating broad agreement among respondents in the stakeholder survey that community acceptability of each method is unlikely to hinder implementation. This was concordant with the findings from community members in Tanzania, who rated each test type generally acceptable.

A study in the Bijagós Islands, Guinea Bissau on different diagnostic tests and sample types for trachoma surveillance (including clinical exams, eye swabs, and finger-prick blood samples) reported that although all the studied test types were generally acceptable, there was a preference among community members for laboratory-based testing; these results were considered more accurate than clinical examination. Additionally, sample types that did not require close proximity to the eye (i.e., finger-prick blood samples) were preferred. Our study had similar results, with participants noting a perception of improved accuracy from laboratory-based methods, although expressing some unease with the eye swab and blood spot procedures, especially with regards to children. This similarity in findings is reassuring given the different locations and population types, indicating some generalizability of the results. Considered in parallel, these results suggest that acceptability would not be a widespread barrier to implementation.

Different studies have shown varying levels of acceptability of blood collection. Research in sub-Saharan Africa has shown that collecting blood or other bodily samples from individuals can be challenging, with fears related to blood-stealing and intentional spreading of disease concerning public health interventions documented since colonial times.²⁷ Individual reticence to participation in a trial in The Gambia involving blood collection via finger stick for malaria

485

486

487

488

489

490

491

492

493

494

495

496

497

498

499

500

501

502

503

504

505

506

screening was linked to fear of blood-taking due to depletion of life force and fear of exploitation.²⁸ In contrast, a study on the feasibility of bloodspot collection for the surveillance of human African trypanosomiasis in the Democratic Republic of the Congo found that refusal to participate in bloodspot collection was rare, although reasons for non-participation were not analysed.²⁹ Finger-prick blood samples are routinely taken for malaria testing,³⁰ which is commonplace in most places that are also trachoma-endemic. ³¹ Our community member participants expressed broad acceptance of blood spots, with two notable exceptions. First, among the Maasai ethnic group one FGD (out of four) noted a general cultural dislike of blood-giving. This may be related to a noted lack of trust of non-Massai visitors, an incomplete understanding of the purpose of interventions, and a perception of misalignment between community and government priorities, which has eroded trust in this institution.³² A study conducted in the Sinya Ward (a Maasai community in Longido District) found that, while this community does perceive trachoma as a problem, ³³ competing priorities can make it difficult to participate in trachoma-related interventions, such as MDA.³² A lack of sensitization around MDA has previously been associated with poor uptake of azithromycin in this area,³⁴ underscoring the need for effective messaging on health programs in these and other underserved communities, which, as we near trachoma elimination, may represent the last foci of TF. Second, concerns explicitly about the purpose of blood tests were raised (among a variety of ethnic groups), with specific fears mentioned around testing for HIV without the participants' consent. These fears were relayed both by community participants themselves and recognized as a potential reason for low community acceptance by public health practitioners. In this regard, the familiarity and commonplace nature of blood testing is a disadvantage, as community

members are aware that their blood samples could be tested for many other diseases, some of

which (such as HIV) still carry a level of stigma.³⁵ However, familiarity with blood spots was also perceived as an advantage of this method, both by community members, who appreciated the lack of pain or harm caused by the sample procedure, and by public health practitioners, who noted experience with sample collection, processing, and testing by an array of health systems in Tanzania.

While public health practitioners in Tanzania did often recognize the familiarity of blood testing (for other diseases) by health systems as an advantage of this method, our study found a lack of acknowledgement of the potential utility of serology for the integration of trachoma monitoring with other disease programs. This group also recognized that a lack of local lab capacity would make the quick processing of blood samples a challenge, which was corroborated as a barrier to implementation by global stakeholders. The Global NTD road map 2021–2030 calls for concerted action to achieve integration across NTD programs and for increased investment in developing lab capacity in order to meet NTD targets. ¹⁹ The long-term benefit of investments in increasing and maintaining lab capacity of health systems for infection testing and serology should be underscored to stakeholders at all levels. A coordinated approach is needed to leverage the investments and achievements made to date across different disease programs, enabling the building, strengthening and maintenance of laboratory capacity and networks. ³⁶

Community members found conjunctival photography to be an acceptable method for trachoma diagnosis, noting a general familiarity with the concept of medical imaging and potential benefits of this method compared to field grading of TF. Another study on the acceptability of conjunctival photography among community members in Tanzania found similar sentiment around the utility of photography for grading borderline cases (contributing to greater overall accuracy), but noted an element of concern among community members regarding the

exposure of children to a photo flash.³⁷ However, this fear pertained only to traditional digital single-lens reflex (DSLR) cameras, compared to photography via smartphone.³⁷ In addition, our study did not find that issues around photo use and confidentiality were a concern among community members. However, these issues were recognized as potential concerns by public health practitioners in our study, as well as both community members and Tropical Data trainers in the previous Tanzanian qualitative study.³⁷ Consent materials for activities incorporating conjunctival photography for research or programmatic use should be very clear as to the risks and benefits of participating.

We found that generally, FGDs with men were more favorable to each of the test types compared to FGDs with women, with FGDs with men more likely to have at least one participant indicate that they would hypothetically allow the children under their care to participate in each test type compared to FGDs with women. A previous systematic review and meta-analysis on the acceptance of the COVID-19 vaccine, which included studies from each WHO region, found that male gender was associated with an increased likelihood of vaccine acceptance. A systematic review on this topic in sub-Saharan Africa found similar results. In terms of care-giving behavior, a multi-country questionnaire similarly found that fathers are more willing than mothers to vaccinate their children against COVID-19, possibly due to differences in risk-taking behaviors among fathers vs. mothers. It may be advisable to target messaging around the safety of and risk of discomfort or adverse consequences from each diagnostic method specifically to women caregivers, especially as they are often the decision-makers in regards to children's healthcare.

The high level of stakeholder agreement that a WHO recommendation of field grading of TF is beneficial indicates that additional WHO guidance around complementary indicators may

be advantageous. In informal workshops, tests for infection and serology have already been advocated for by WHO, ¹⁵ and the forthcoming guidelines on their use are eagerly awaited.

Seventy unique questions regarding knowledge gaps preventing the interpretation and implementation of complementary indicators were identified by global stakeholders. The collation and categorization of these questions will hopefully serve as a useful resource for helping to define future research priorities as we approach the trachoma elimination endgame.

Our study had several limitations. Messaging that not all tests would yield individual results was included in the FGD topic guide and stated by the research assistant while conducting the FGD. However, it is clear from the transcripts that participants did not adequately understand that they would not always receive individual results for each sample type, making conclusions difficult to apply to surveillance settings, where participants could not expect individual results and/or treatment. Furthermore, we note that asking community members if they would hypothetically participate in each sample collection type may yield different results than actually presenting participants with the opportunity to be tested. In addition, community FGDs and IDIs only took place in a selection of sites within one country. There are likely to be differing views across the trachoma-endemic world.

In attempting to evaluate the opinion of a variety of trachoma stakeholders, the stakeholder survey was disseminated to as wide an audience as possible, resulting in an opportunistic sample. While an opportunistic sample has implications for generalizability, the multiple avenues of survey dissemination, the offering of multiple languages of the survey, and the diverse geographic representation of respondents indicate that the results are likely fairly representative of trachoma stakeholders as a whole.

Strengths and barriers from the IDIs were used to formulate the questions for the stakeholder survey. In order to preserve the intent of these responses, the items in the stakeholder survey could have been perceived as overly positive (for the strengths) and negative (for the barriers), which may have had an effect in biasing stakeholders' level of agreement with each item. In addition, the factual accuracy of the statements offered by the IDIs (for example, that one test may be more "accurate" than another) is debatable, which may have hindered interpretation of participants' agreement with these items. There may have also been potential strengths and barriers to each method not identified by IDI respondents (such as the potential benefit of being able to test blood spots for multiple infections). In each case, to avoid biasing the selection of strengths and barriers presented in the questionnaire, care was taken to preserve the original content and meaning from the IDIs. However, future surveys may wish to provide more comprehensive lists of strengths and barriers and more neutral question wording (for example, by allowing respondents to rate the acceptability of different methods, rather than their agreement with subjective statements).

Future work would be needed in order to study the opinions of communities in other regions to have more confidence in the generalizability of our results. A deeper exploration into the attitudes and perceptions of blood testing among the Maasai ethnic group, along with the effectiveness of potential education or sensitization strategies, is warranted in order to ensure this group is equitably represented in future trachoma programming. In addition, a study of non-response rates in studies where additional indicators are collected would yield information about the acceptability of different sample collection methods for trachoma detection during real-world program activities.

Conclusions

We found that conjunctival photography, infection testing, and serology were all generally acceptable to community members in Tanzania. Critical themes included participants not wanting to suffer harm from the diagnostic process and the importance of (perceived) test accuracy. Many of the perceived disadvantages mentioned by community members in Tanzania, such as fear of undue discomfort or adverse consequences of participating in the diagnostic process or mistrust of the test purpose (for serology) are potential focus areas for outreach by healthcare workers and other partners prior to implementation. This need for community education on the risks and benefits of participation of each of the methods was underscored in interviews with public health practitioners in Tanzania. According to both Tanzanian public health practitioners and global stakeholders, questions of feasibility remain, especially for infection testing and serology. The fact that in general, all methods were acceptable to community members is positive, as it may be that each indicator has a role to play for trachoma elimination surveillance purposes.

613

614

615

616

617

618

619

620

621

622

623

624

625

626

627

628

629

630

631

632

633

634

Funding Study activities were funded by the International Trachoma Initiative. AWS is a staff member of the World Health Organization. RBs salary was funded by the Wellcome Trust (206275/Z/17/Z). **Competing Interests** I have read the journal's policy and the authors of this manuscript have the following competing interests: KKR, PJH, and PME are employees of the International Trachoma Initiative (ITI), a program of The Task Force for Global Health, which receives an operating budget and research funds from Pfizer Inc., the manufacturers of Zithromax (azithromycin). EMHE receives salary support from ITI, and PM and JMM were contractors of ITI for the duration of field activities in Tanzania. Pfizer, Inc. had no role in in the study conception or design; data collection, analysis, or interpretation; writing of the report; or the decision to publish this work. **Authors' Contributions** KKR, EMHE, and AWS conceived of the study; KKR, RB, TDH, GK, TBM, and EMHE designed the study protocols; PME and PJH reviewed the Tanzania study protocol; GK, JMM, PM, SGM, and KKR carried out field coordination; KKR, JMM, and PM carried out data collection; KKR conducted data analysis; KKR, TBM, JMM, PM, and EMHE conducted data interpretation; KKR prepared the original draft of the manuscript; all authors critically reviewed the manuscript and approved the final manuscript for publication. Acknowledgements The authors which to thank the participants of the focus group discussions, in-depth interviews, and the survey respondents for their involvement in this project. Data availability statement Study data will be made available upon reasonable request to the corresponding author.

Disclaimer

The authors alone are responsible for the views expressed in this article and they do not necessarily represent the views, decisions or policies of the institutions with which they are affiliated.

References

- 641 Gambhir M, Grassly NC, Burton MJ, Solomon AW, Taylor HR, Mabey DC, et al. Estimating the
- 642 Future Impact of a Multi-Pronged Intervention Strategy on Ocular Disease Sequelae Caused by
- 643 Trachoma: A Modeling Study. Ophthalmic Epidemiol. 2015;22(6):394-402.
- 644 World Health Organization. Validation of elimination of trachoma as a public health problem.
- 645 Geneva, Switzerland: World Health Organization; 2016.
- 646 World Health Organization. Report of the third Global Scientific Meeting on Trachoma
- 647 Elimination. Baltimore, MD: Johns Hopkins University; 2010.
- 648 Wright HR, Taylor HR. Clinical examination and laboratory tests for estimation of trachoma
- 649 prevalence in a remote setting: what are they really telling us? Lancet Infect Dis. 2005;5(5):313-20.
- 650 Ramadhani AM, Derrick T, Macleod D, Holland MJ, Burton MJ. The Relationship between Active
- 651 Trachoma and Ocular Chlamydia trachomatis Infection before and after Mass Antibiotic Treatment. PLoS 652 Negl Trop Dis. 2016;10(10):e0005080.
- 653 Solomon AW, Harding-Esch E, Alexander ND, Aguirre A, Holland MJ, Bailey RL, et al. Two doses 6.
- 654 of azithromycin to eliminate trachoma in a Tanzanian community. N Engl J Med. 2008;358(17):1870-1.
- 655 Butcher R, Sokana O, Jack K, Sui L, Russell C, Last A, et al. Clinical signs of trachoma are prevalent
- 656 among Solomon Islanders who have no persistent markers of prior infection with Chlamydia
- 657 trachomatis. Wellcome Open Res. 2018;3:14.
- 658 Trotignon G, Jones E, Engels T, Schmidt E, McFarland DA, Macleod CK, et al. The cost of mapping
- 659 trachoma: Data from the Global Trachoma Mapping Project. PLoS Negl Trop Dis. 2017;11(10):e0006023-
- 660 e.
- 661 9. Harding-Esch EM, Burgert-Brucker CR, Jimenez C, Bakhtiari A, Willis R, Bejiga MD, et al. Tropical
- Data: Approach and Methodology as Applied to Trachoma Prevalence Surveys. Ophthalmic 662
- 663 Epidemiology. 2023;30(6):544-60.
- 664 10. Jimenez C, Gower E, Harding-Esch E, West SK. Harnessing photography and image recognition
- 665 technology to aid in the elimination of trachoma. Community Eye Health. 2022;35(114):24.
- 666 Solomon AW, Pavluck AL, Courtright P, Aboe A, Adamu L, Alemayehu W, et al. The Global
- 667 Trachoma Mapping Project: Methodology of a 34-Country Population-Based Study. Ophthalmic
- 668 Epidemiology. 2015;22(3):214-25.
- 669 Harding-Esch EM, Naufal F, Saboya M, Jimenez C, West SK. Use of photography for support of
- 670 trachoma grading: progress report. 2021.
- 671 13. Martin DL, Saboyà-Díaz MI, Abashawl A, Alemayeh W, Gwyn S, Hooper PJ, et al. The use of
- 672 serology for trachoma surveillance: Current status and priorities for future investigation. PLoS Negl Trop
- 673 Dis. 2020;14(9):e0008316-e.
- 674 World Health Organization. Trachoma Alternative Indicators Study Data review. Geneva,
- 675 Switzerland: World Health Organization; 2016.
- 676 World Health Organization. Informal consultation on end-game challenges for trachoma
- 677 elimination. Task Force for Global Health, Decatur, United States of America. Geneva: World Health
- 678 Organization; 2022. 7–9 December 2021.
- 679 World Health Organization. WHO handbook for guideline development - 2nd ed. Geneva,
- 680 Switzerland: World Health Organization; 2014.
- 681 Senyonjo L, Downs P, Schmidt E, Bailey R, Blanchet K. Lessons learned for surveillance strategies 17.
- 682 for trachoma elimination as a public health problem, from the evaluation of approaches utilised by
- 683 Guinea worm and onchocerciasis programmes: A literature review. PLoS Negl Trop Dis.
- 684 2021;15(1):e0009082-e.
- 685 Oldenburg CE, Aragie S, Amza A, Solomon AW, Brogdon J, Arnold BF, et al. Can we eradicate
- 686 trachoma? A survey of stakeholders. Br J Ophthalmol. 2021;105(8):1059-62.

- 687 19. World Health Organization. Ending the neglect to attain the Sustainable Development Goals A
- road map for neglected tropical diseases 2021–2030. Geneva, Switzerland World Health Organization;
- 689 2020.
- 690 20. International Trachoma Initiative. Global Atlas of Trachoma Decatur, Georgia 2020 [Available
- 691 from: trachomaatlas.org].
- 692 21. Magnani R, Sabin, Keith, Saidel, Tobi, Heckathorn, Douglas. Review of sampling hard-to-reach
- and hidden populations for HIV surveillance. AIDS. 2005;19:S67-S72.
- 694 22. Lumivero. NVivo 13 (2020, R1).
- 695 23. Gale NK, Heath G, Cameron E, Rashid S, Redwood S. Using the framework method for the
- analysis of qualitative data in multi-disciplinary health research. BMC Medical Research Methodology.
- 697 2013;13(1):117.
- 698 24. SurveyMonkey Inc. San Mateo, California, USA [Available from: www.surveymonkey.com].
- 699 25. R Core Team. R: A language and environment for statistical computing. Vienna, Austria: R
- 700 Foundation for Statistical Computing; 2021.
- 701 26. Sahota RS, Sanha S, Last A, Cassama E, Goncalves A, Kelly AH, et al. Acceptability and perceived
- 702 utility of different diagnostic tests and sample types for trachoma surveillance in the Bijagos Islands,
- 703 Guinea Bissau. Trans R Soc Trop Med Hyg. 2021;115(8):847-53.
- 704 27. Geissler PW, Pool R. Editorial: Popular concerns about medical research projects in sub-Saharan
- Africa a critical voice in debates about medical research ethics. Tropical Medicine & International
- 706 Health. 2006;11(7):975-82.
- 707 28. O'Neill S, Dierickx S, Okebe J, Dabira E, Gryseels C, d'Alessandro U, et al. The Importance of
- 708 Blood Is Infinite: Conceptions of Blood as Life Force, Rumours and Fear of Trial Participation in a Fulani
- 709 Village in Rural Gambia. PLoS One. 2016;11(8):e0160464.
- 710 29. Inocencio da Luz R, Phanzu DM, Kiabanzawoko ON, Miaka E, Verlé P, De Weggheleire A, et al.
- 711 Feasibility of a dried blood spot strategy for serological screening and surveillance to monitor
- 712 elimination of Human African Trypanosomiasis in the Democratic Republic of the Congo. PLoS Negl Trop
- 713 Dis. 2021;15(6):e0009407.
- 714 30. World Health Organization. Malaria surveillance, monitoring and evaluation: a reference
- 715 manual. Geneva, Switzerland World Health Organization; 2018.
- 716 31. World Health Organization. World malaria report 2022. Geneva; 2022.
- 717 32. Mtuy TB, Bardosh K, Ngondi J, Mwingira U, Seeley J, Burton M, et al. Understanding hard-to-
- 718 reach communities: local perspectives and experiences of trachoma control among the pastoralist
- 719 Maasai in northern Tanzania. J Biosoc Sci. 2021;53(6):819-38.
- 720 33. Mtuy TB, Burton MJ, Mwingira U, Ngondi JM, Seeley J, Lees S. Knowledge, perceptions and
- 721 experiences of trachoma among Maasai in Tanzania: Implications for prevention and control. PLoS Negl
- 722 Trop Dis. 2019;13(6):e0007508-e.
- 723 34. Desmond N, Solomon AW, Massae PA, Lema N, Anemona A, Foster A, et al. Acceptability of
- 724 azithromycin for the control of trachoma in Northern Tanzania. Trans R Soc Trop Med Hyg.
- 725 2005;99(9):656-63.
- 726 35. Gooden TE, Mkhoi ML, Mdoe M, Mwalukunga LJ, Senkoro E, Kibusi SM, et al. Barriers and
- 727 facilitators of people living with HIV receiving optimal care for hypertension and diabetes in Tanzania: a
- 728 qualitative study with healthcare professionals and people living with HIV. BMC Public Health.
- 729 2023;23(1):2235.
- 730 36. Mfuh KO, Abanda NN, Titanji BK. Strengthening diagnostic capacity in Africa as a key pillar of
- public health and pandemic preparedness. PLOS Glob Public Health. 2023;3(6):e0001998.
- 732 37. Bisanzio D, Butcher R, Turbé V, Matsumoto K, Dinesh C, Massae P, et al. Accuracy, acceptability
- 733 and feasibility of photography for use in trachoma surveys: a mixed methods study in Tanzania. Int
- 734 Health. 2023.

- 735 38. Wang Q, Yang L, Jin H, Lin L. Vaccination against COVID-19: A systematic review and meta-
- analysis of acceptability and its predictors. Prev Med. 2021;150:106694.
- 737 39. Azanaw J, Endalew M, Zenbaba D, Abera E, Chattu VK. COVID-19 vaccine acceptance and
- associated factors in 13 African countries: A systematic review and meta-analysis. Front Public Health.
- 739 2022;10:1001423.

- 740 40. Goldman RD, Yan TD, Seiler M, Parra Cotanda C, Brown JC, Klein EJ, et al. Caregiver willingness
- 741 to vaccinate their children against COVID-19: Cross sectional survey. Vaccine. 2020;38(48):7668-73.
- 742 41. McCauley AP, West S, Lynch M. Household decisions among the Gogo people of Tanzania:
- 743 determining the roles of men, women and the community in implementing a trachoma prevention
- 744 program. Soc Sci Med. 1992;34(7):817-24.